RxDoctor Payments Data

Daniel Schimmel

Interventional Cardiology · Chicago, ILNPI 1093974693

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (31.0%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Penumbra, Inc. at 26.5% of the total. Among interventional cardiology clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$79,046in general payments, 2019–2025

Across 232 payments — averaging $340.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Penumbra, Inc.$21K
  • Inari Medical, Inc.$17K
  • Boston Scientific$11K
  • Medtronic$10K
  • Stryker$9K
  • Inquis Medical, Inc.$6K
  • plus $5K from 21 others
$141,478in research payments, 2019–2025

Across 71 payments — averaging $1992.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Penumbra, Inc.$68K
  • Inari Medical, Inc.$37K
  • EKOS Corporation$15K
  • Daiichi Sankyo Inc.$11K
  • Boston Scientific$10K
  • Shockwave Medical, Inc$2K

What the payments were for

  • Consulting fees$24,47531%
  • Speaking & faculty fees$23,00029%
  • Travel & lodging$20,62126%
  • Food & beverage$10,95014%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$79,046 in reported general payments places this provider in the 90th percentile of 303 interventional cardiology providers in Illinois.

See all interventional cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$224,527
Medicare patients
414
Services billed
1,326

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban34$41,672
XareltoRivaroxaban26$30,168
Repatha SureclickEvolocumab21$19,336
JardianceEmpagliflozin15$17,336
Praluent PenAlirocumab11$10,175
Ranolazine ErRanolazine13$3,456
Ezetimibe110$3,218
Metoprolol Succinate178$3,077
Atorvastatin Calcium241$2,861
ClopidogrelClopidogrel Bisulfate176$2,490
Rosuvastatin Calcium98$1,273
Carvedilol59$848
Prasugrel Hcl14$781
Amlodipine Besylate140$772
Losartan Potassium61$660

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →